The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
yea agree MM take the mick... but at 21p i paid, it was cheap... not looking to trade it this one will stay untill dividend pays on scancell ...
Been following the price since yours of the other day. Interesting theory of yours,so thought I'd watch and see. Dealing in this looks nuts, spread to drive a bus thru and no movement, so when I see a level 2 like that I think,"weird"! Assume the original offer taken out and paid up over (maybe attempt to promote interest)? i'll keep it on the watch list but too rich for me ATM.
yea funny, but why someone pay 30p against ask of 26p ? you bought in then m8 what price you pay here
Desperate Buyers??????
WOW Movement!
SCLP thanku Lucinda for the post ..SCLP I'm glad we have a new near term of 36p from Shri9. That's a relief! The advice from the wise is "there is a bid coming." In the meantime the price will take its upward course until an offer price is known. As many have pointed out. Scancell has a FOR SALE sign attached to it. I see our lovely CEO Lindy Durrant has been appointed to Biovest International's Scientific Advisory Board. Now Ladies and Gentlemen that's one company that might just swallow up Scancell for starters, that is its parent might, Accentia Biopharmaceuticals, Inc. They have a cancer vaccine in Phase III to combat lymphoma but they would love SCIB1 big time and Scancell's ImmunoBody® technology even more. -- Lindy G. Durrant, Ph.D., Professor, Faculty of Medicine & Health Sciences and Chair in Cancer Immunotherapy, Department of Clinical Oncology, University of Nottingham (UK) -- An internationally recognized immunologist in the field of tumor therapy, Dr. Durrant has worked for more than 20-years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She is currently running clinical trials in colorectal cancer, osteosarcoma and malignant melanoma. Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma. http://www.marketwatch.com/story/biovest-announces-international-members-of-its-cancer-vaccine-scientific-advisory-board-2012-04-03 http://www.accentia.net/
U dont have to trade this one, when scancell sell out, the fund will pay a massive dividend. so just forget about it ok... it will revalue once a year, in the portfolio Select and Scancell are the winners.
I had a change of heart I brought nano and oxa today. I am very pleased with those. thanks for the heads up.
IMHO ... as there is always risk !!
nice one... buy and hold it will pay off !!
I am buying these now. I have also purchased oxa today.
There is a miss match on SCLP Verse OXT…. OXT (OXT is a venture fund) last valuation of it’s portfolio was at 27p per share as of Nov 2011 the current market cap is £920,000 with a share price off 17p approx. but it holds as part of its portfolio 8,333,300 shares in Scancell The value at 17p = £1.41m plus. So the real value of this fund is well over £2,000,000 or 40p per share, every time Scancell jumps OXT should track it, but the market has NOT connected the two yet … get in while you can !!! http://www.oxfordtechnology.com/index.php?id=18&type=vct The un-audited net asset value per ordinary share as at 30 November 2011 was 27p. This is a rise of 1p from the last quarter ending 31 August 2011. The total number of ordinary shares in issue is 5,431,655 (As a footnote just it’s holding in Scancell = 26p per share) The spread is terrible, but that will tighten as MM excess stock gets bought up. Good luck all